Design of the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT) trial in symptomatic intracranial stenosis
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Zaidat, Osama O.Castonguay, Alicia C.
Fitzsimmons, Brian-Fred
Woodward, Britton Keith
Wang, Zhigang
Killer-Oberpfalzer, Monika
Wakhloo, Ajay K.
Gupta, Rishi
Kirshner, Howard
Eliasziw, Misha
Thomas Megerian, J.
Shetty, Sujith
Yoklavich Guilhermier, Meg
Barnwell, Stanley
Smith, Wade S.
Gress, Daryl R.
UMass Chan Affiliations
Department of RadiologyDocument Type
Journal ArticlePublication Date
2013-10-01Keywords
AdolescentAdult
Aged
Aged, 80 and over
Clinical Protocols
Constriction, Pathologic
Female
Humans
Intracranial Arteriosclerosis
Male
Middle Aged
Research Design
Stents
Stroke
Cardiovascular Diseases
Neurology
Radiology
Metadata
Show full item recordAbstract
BACKGROUND: Patients with high-grade symptomatic intracranial stenosis ( > /= 70%) have an increased risk of recurrent stroke despite medical treatment with antiplatelet or anticoagulant therapy. Intracranial stenting has been proposed as a viable treatment option for this high-risk patient population; however, evaluation of this therapy in randomized multicenter trials is needed. In this article, we present the design and methods of the Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT) trial for symptomatic intracranial stenosis. METHODS: The VISSIT trial is a randomized control study designed to evaluate the safety, probable benefit, and effectiveness of the PHAROS Vitesse neurovascular balloon-expandable stent system plus medical therapy versus medical therapy alone in patients with cerebral or retinal ischemia due to neurovascular stenosis ( > /= 70%) for preventing the primary composite end point: stroke in the same territory (distal to the target lesion) as the presenting event within 12 months of randomization or hard transient ischemic attack in the same territory (distal to the target lesion) as the presenting event from day 2 through month 12 postrandomization. RESULTS: Enrollment began in February 2009 and was halted in January 2012 with 112 subjects enrolled into the study. Clinical follow-up will continue for the planned period of 12 months postrandomization. CONCLUSIONS: The VISSIT trial may provide valuable insight into the use of balloon-expandable intracranial stent as a treatment option for high-risk patients. Lessons learned from this trial may better guide future clinical trial design on best patient selection, stenting techniques, and periprocedural management.Source
J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1131-9. doi: 10.1016/j.jstrokecerebrovasdis.2012.10.021. Epub 2012 Dec 21. Link to article on publisher's siteDOI
10.1016/j.jstrokecerebrovasdis.2012.10.021Permanent Link to this Item
http://hdl.handle.net/20.500.14038/30510PubMed ID
23261207Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.jstrokecerebrovasdis.2012.10.021